Harvard College

Tufts College

Vilnius University

Other

Marc W Kirschner

Noriyuki Kinoshita

Randall W King

Kevin D Lustig

Yifat Merbl

David A Weitz

Linas Mazutis

Allon Moshe Klein

Ilke Akartuna

Alexander Aristarkov

Fiona Townsley

Joan V Ruderman

Esther Eytan

Hongtao Yu

Avram Hershko

Graeme C McAlister

Steven P Gygi

Wilhelm Haas

Martin Helmut Wuhr

Kristen Kroll

Thomas J McGarry

Victor Chun Li

Stefan Jentsch

Leonid Peshkin

P Renee Yew

Ramin Rad

P Todd Stukenberg

Debrabata RayChaudhuri

Jan-Michael Peters

Debabrata RayChaudhuri

Seungeun Oh

Graeme Conrad McAlister

Graeme Conrad Mcalister

A method for measuring a composition of a biological sample is disclosed. A stimulated Raman scattering (SRS) image of the biological sample is received. The effect of light scattering in the received SRS image is computationally removed. An absolute concentration of total protein, total lipid, and/or water from the biological sample is determined.

In situ measurement of absolute concentrations by normalized Raman imaging

Methods for the large scale identification of post-translational modification states of proteins and enzyme activities for carrying out post-translational modification reactions involve the analysis of functional extracts from fresh and frozen samples using protein arrays. The methods and kits of the present invention can be used to analyze and characterize compounds for their effects on post-translational modifications and their pathways. The methods and kits can also be used to diagnose and characterize a wide variety of diseases and medical conditions, including cancer, neurodegenerative diseases, immune diseases, infectious diseases, genetic diseases, metabolic conditions, and drug effects using cells or body fluids of a patient.

Diagnostic method based on large scale identification of post-translational modification of proteins

The present invention generally relates to microfluidics and labeled nucleic acids. For example, certain aspects are generally directed to systems and methods for labeling nucleic acids within microfluidic droplets. In one set of embodiments, the nucleic acids may include 'barcodes' or unique sequences that can be used to distinguish nucleic acids in a droplet from those in another droplet, for instance, even after the nucleic acids are pooled together. In some cases, the unique sequences may be incorporated into individual droplets using particles and attached to nucleic acids contained within the droplets (for example, released from lysed cells). In some cases, the barcodes may be used to distinguish tens, hundreds, or even thousands of nucleic acids, e.g., arising from different cells or other sources.

Systems and methods for barcoding nucleic acids

Described herein are methods relating to the differentiation of stem cells to more differentiated phenotypes, e.g. to terminally differentiated cell types and/or precursors thereof. In some embodiments, the methods relate to contacting the stem cells with differentiation factors and halting the cell cycle, thereby increasing the rate of differentiation.

Methods for differentiation

Described herein are methods of inhibiting mitosis, treating cancer and/or treating immune disorders through the use of agents that inhibit FAT10 and/or the FAT10 pathway.

Cancer treatment and immune system regulation through FAT10 pathway inhibition

Embodiments are directed to a method, a computer readable medium encoded with instructions that, when executed, perform a method, and a system for performing mass spectrometry analysis. Molecules of different samples may be labeled with a chemical tag, allowing a multiplexed analysis of multiple samples. The labeled molecules may be fragmented, each fragmented molecule creating at least two separate ions. The relative abundance of each of the heavier ions, which may comprise the original molecule from the sample, may be measured. A relative abundance of the labeled molecules in each of the samples may be determined from the measured relative abundances of the heavier ions.

Accurate and interference-free multiplexed quantitative proteomics using mass spectrometry

Described herein are methods of inhibiting mitosis, treating cancer and/or treating immune disorders through the use of agents that inhibit FAT 10 and/or the FAT 10 pathway.

The present invention provides in vitro assays, e.g., FtsZ GTPase assays, and/or in vivo assays and methods of use thereof to identify particular compounds and combinations of compounds that affect microbial cell division. The invention further provides such compounds and compound combinations, including combinations that result in inhibition of cell survival or growth when present together at concentrations below their individual MICs. Certain of the compound combinations display synergism. Certain of the combinations include a compound that inhibits FtsZ GTPase activity and a compound that inhibits cell growth by a mechanism other than inhibition of FtsZ GTPase activity. The present invention further provides pharmaceutical compositions that have anti-microbial activity and methods of treating microbial infections.

Compound combinations for inhibiting cell division and methods for their identification and use

The present invention provides novel in vivo assay systems and methods of using these assays systems to identify compounds that affect microbial cell division. The present invention further provides pharmaceutical compositions that have anti-microbial activity and methods of treating microbial infections.

In vivo assay for identification of antimicrobial agents

Disclosed herein are compositions and methods which are useful in the identification and isolation of components involved in transmembrane receptor-mediated signaling. Such components include the receptors themselves (e.g., tyrosine kinase receptors, cytokine receptors and tyrosine phosphatase receptors), as well as ligands which bind the receptors and modulators of the downstream intracellular catalytic event which characterizes receptor-mediated signalling. Two novel ligands for the FGF receptor and the nucleotide sequences encoding them are also described.

Isolated FGF receptor

The claimed invention pertains to a novel protein called Geminin which is able to inhibit DNA replication and/or induce neurogenesis. The claimed invention includes the amino acid sequence, the nucleic acid sequence, and various domains thereof. The invention further relates to methods for treating patients with a proliferative disease by administering an effective amount of the Geminin protein and/or nucleic acid. Similarly, the claimed inventions pertains to methods for treating various neurological disorders by administering neuronal cells which were differentiated by exposure to Geminin.

Geminin gene and protein

Disclosed are novel human and clam ubiquitin carrier polypeptides involved in the ubiquitination of cyclins A and/or B. Also disclosed are inhibitors of such polypeptides, nucleic acids encoding such polypeptides and inhibitors, antibodies specific for such polypeptides, and methods of their use.

Cyclin-selective ubiquitin carrier polypeptides

Method of isolating receptor and ligand DNA

Growing community of inventors

Newton, MA, United States of America

Marc W Kirschner